Travere Therapeutics (TVTX) Interest Coverage Ratio (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Interest Coverage Ratio came in at 16.05 in Q1 2026, down 9.07% YoY from 17.65 in Q1 2025, and down 8.89% on a QoQ basis from 14.74 in Q4 2025.
Travere Therapeutics (TVTX) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Interest Coverage Ratio data on file, last reported at 16.05 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 9.07% year-over-year to 16.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.62 (up 77.92% YoY) and the FY2025 annual result came in at 0.17, up 81.98% from the prior year.
- Interest Coverage Ratio slipped to 16.05 in Q1 2026, from 14.74 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 9.06 in Q3 2025 to a low of 138.67 in Q4 2024.
- A 5-year average of 30.72 and a median of 28.79 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio tumbled 312.04% — and 2025, when it surged 145.19%.
- Tracing TVTX's Interest Coverage Ratio over 5 years: stood at 30.81 in 2022, then slipped by 9.23% to 33.65 in 2023, then sank by 312.04% to 138.67 in 2024, then surged by 89.37% to 14.74 in 2025, then fell by 8.89% to 16.05 in 2026.
- The last three Interest Coverage Ratio figures came in at 16.05 (Q1 2026), 14.74 (Q4 2025), and 9.06 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.01 |
| Mar 31, 2026 | -16.05 |
| Dec 31, 2025 | -14.74 |
| Sep 30, 2025 | 9.06 |
| Jun 30, 2025 | -0.58 |
| Mar 31, 2025 | -14.72 |
| Dec 31, 2024 | -138.67 |
| Sep 30, 2024 | -20.05 |
| Jun 30, 2024 | -24.28 |
| Mar 31, 2024 | -49.73 |
| Dec 31, 2023 | -33.65 |
| Sep 30, 2023 | -32.82 |
| Jun 30, 2023 | -37.13 |
| Mar 31, 2023 | -33.58 |
| Dec 31, 2022 | -30.81 |
| Sep 30, 2022 | -29.50 |
| Jun 30, 2022 | -26.18 |
| Mar 31, 2022 | -28.79 |
| Dec 31, 2021 | -39.43 |
| Sep 30, 2021 | -18.38 |